Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Zentalis Pharmaceuticals Inc (ZNTL)

Zentalis Pharmaceuticals Inc (ZNTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 213,795
  • Shares Outstanding, K 71,265
  • Annual Sales, $ 0 K
  • Annual Income, $ -292,190 K
  • EBIT $ -221 M
  • EBITDA $ -232 M
  • 60-Month Beta 1.83
  • Price/Sales 5.25
  • Price/Cash Flow N/A
  • Price/Book 0.59

Options Overview Details

View History
  • Implied Volatility 677.80% ( +287.46%)
  • Historical Volatility 91.88%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 677.80% on 12/20/24
  • IV Low 13.38% on 08/14/24
  • Put/Call Vol Ratio 0.60
  • Today's Volume 160
  • Volume Avg (30-Day) 118
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 3,341
  • Open Int (30-Day) 3,308

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.83
  • Number of Estimates 8
  • High Estimate -0.66
  • Low Estimate -1.01
  • Prior Year -0.83
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.80 +7.33%
on 12/19/24
4.00 -25.00%
on 12/09/24
-0.13 (-4.15%)
since 11/20/24
3-Month
2.66 +12.78%
on 10/31/24
4.44 -32.43%
on 11/13/24
-1.22 (-28.91%)
since 09/20/24
52-Week
2.66 +12.78%
on 10/31/24
18.07 -83.40%
on 02/28/24
-10.56 (-77.88%)
since 12/20/23

Most Recent Stories

More News
Zentalis Pharmaceuticals Appoints Wendy Chang as Chief People Officer and Haibo Wang as Chief Business Officer

Zentalis Pharmaceuticals announced the appointments of Wendy Chang and Haibo Wang to leadership positions to advance azenosertib's development.Quiver AI SummaryZentalis Pharmaceuticals announced the appointment...

ZNTL : 3.00 (+2.39%)
Zentalis Pharmaceuticals Announces Key Management Appointments

ZNTL : 3.00 (+2.39%)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZNTL : 3.00 (+2.39%)
Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib

ZNTL : 3.00 (+2.39%)
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZNTL : 3.00 (+2.39%)
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77%

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Although death rates for some cancers are declining, the world is facing a sharp increase in cancer...

ONCY : 0.8310 (-6.36%)
ZNTL : 3.00 (+2.39%)
TIL : 20.61 (+2.64%)
IMRX : 2.00 (+8.70%)
ZLAB : 26.72 (+1.91%)
ONC.TO : 1.19 (-9.16%)
Why Shares of Zentalis Pharmaceuticals Dropped This Week

A rash of insider selling meant the stock gave back some of its gains from last week.

RHHBY : 34.5000 (+0.76%)
ZNTL : 3.00 (+2.39%)
Newman Ferrara LLP Announces Corporate Governance Investigations of Zentalis Pharmaceuticals, Inc. (ZNTL)

Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) (“Zentalis” or the “Company”). The investigations...

ZNTL : 3.00 (+2.39%)
Moore Kuehn, PLLC Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

/PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Zentalis...

ZNTL : 3.00 (+2.39%)
Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update

Strengthened leadership team with the appointment of additional industry veterans, including CEO Dr. Kimberly Blackwell and Chairman Dave Johnson Received...

ZNTL : 3.00 (+2.39%)

Business Summary

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company's lead programs consist of ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative...

See More

Key Turning Points

3rd Resistance Point 3.31
2nd Resistance Point 3.21
1st Resistance Point 3.10
Last Price 3.00
1st Support Level 2.89
2nd Support Level 2.79
3rd Support Level 2.68

See More

52-Week High 18.07
Fibonacci 61.8% 12.18
Fibonacci 50% 10.36
Fibonacci 38.2% 8.55
Last Price 3.00
52-Week Low 2.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar